Yüklüyor......
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and the US for use in patients with type 2 diabetes...
Kaydedildi:
| Yayımlandı: | Ther Adv Endocrinol Metab |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406879/ https://ncbi.nlm.nih.gov/pubmed/25941564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018814560735 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|